Journal Article

DKFZ-2023-00399

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination.

Mühlenbruch, L.DKFZ* ; Abou-Kors, T. ; Dubbelaar, M. L. ; Bichmann, L. ; Kohlbacher, O. ; Bens, M. ; Thomas, J. ; Ezić, J. ; Kraus, J. M. ; Kestler, H. A. ; von Witzleben, A. ; Mytilineos, J. ; Fürst, D. ; Engelhardt, D. ; Doescher, J. ; Greve, J. ; Schuler, P. J. ; Theodoraki, M.-N. ; Brunner, C. ; Hoffmann, T. K. ; Rammensee, H.-G.DKFZ* ; Walz, J.DKFZ* ; Laban, S.

2023
Nature Publ. Group Edinburgh

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41416-023-02197-y

Abstract: The immune peptidome of OPSCC has not previously been studied. Cancer-antigen specific vaccination may improve clinical outcome and efficacy of immune checkpoint inhibitors such as PD1/PD-L1 antibodies.Mapping of the OPSCC HLA ligandome was performed by mass spectrometry (MS) based analysis of naturally presented HLA ligands isolated from tumour tissue samples (n = 40) using immunoaffinity purification. The cohort included 22 HPV-positive (primarily HPV-16) and 18 HPV-negative samples. A benign reference dataset comprised of the HLA ligandomes of benign haematological and tissue datasets was used to identify tumour-associated antigens.MS analysis led to the identification of naturally HLA-presented peptides in OPSCC tumour tissue. In total, 22,769 peptides from 9485 source proteins were detected on HLA class I. For HLA class II, 15,203 peptides from 4634 source proteins were discovered. By comparative profiling against the benign HLA ligandomic datasets, 29 OPSCC-associated HLA class I ligands covering 11 different HLA allotypes and nine HLA class II ligands were selected to create a peptide warehouse.Tumour-associated peptides are HLA-presented on the cell surfaces of OPSCCs. The established warehouse of OPSCC-associated peptides can be used for downstream immunogenicity testing and peptide-based immunotherapy in (semi)personalised strategies.

Note: 2023 May;128(9):1777-1787

---

Contributing Institute(s):

1. DKTK TU zentral (TU01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2023

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---